

PATENT

12273-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Group Art Unit: to be assigned
)	
LANGRIDGE, William H.R. et al.)	Examining Attorney:
)	to be assigned
Serial No.: to be assigned)	
)	
Filed: January 29, 2001)	
)	
For: Transgenic Plant-Based Vaccines)	Pasadena, California

1c960 U.S. PTO
09/771536
01/29/01

STATEMENT IN ACCORDANCE WITH 37 CFR 1.821(c) and (e)

BOX PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D. C. 20231

Dear Sir:


Enclosed with this Statement is the above-identified United States application, including a Sequence Listing and a computer readable form of the sequence listing filed herewith in accordance with 37 CFR 1.821(c) and (e).

37 CFR 1.1821(f) - I hereby state that the content of the paper and computer readable copies of the Sequence Listing submitted herewith in accordance with 37 CFR 1.1821(c) and (e),

"EXPRESS MAIL" mailing label number **EL4422633472US**

Date of Deposit **January 29, 2001**

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D. C. 20231.


Signature

ELAINE PORTER
Typed or Printed Name of Person Mailing Paper or Fee

PATENT

12273-3

respectively, are the same.

The Commissioner is hereby authorized to charge payment of any fees associated with this communication to Deposit Account No. 19-2090.

Respectfully submitted,

SHELDON & MAK
a Professional Corporation

Date: January 29, 2001

By David Farah
David A. Farah, M.D.
Reg. No. 38,134

225 South Lake Avenue
9th Floor
Pasadena, CA 91101
626/796-4000

105210363460